Skip to main content

Human Matrilin-3 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF3017

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF3017
AF3017-SP

Key Product Details

Species Reactivity

Human

Applications

Blockade of Receptor-ligand Interaction, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Matrilin-3

Specificity

Detects human Matrilin-3 in direct ELISAs and Western blots. In Western blots, approximately 50% cross-reactivity with recombinant mouse Matrilin-3 is observed and less than 1% cross-reactivity with recombinant human (rh) Matrilin-2 and rhMatrilin-4 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Applications for Human Matrilin-3 Antibody

Application
Recommended Usage

Blockade of Receptor-ligand Interaction

In a functional ELISA, 0.03-0.1 µg/mL of this antibody will block 50% of the binding of 50 ng/mL of Recombinant Human Matrilin-3 (Catalog # 3017-MN) to immobilized Recombinant Human COMP/Thrombospondin-5 (Catalog # 3134-CP) coated at 2 µg/mL (100 µL/well). At 0.5 μg/mL, this antibody will block >90% of the binding.

Western Blot

0.1 µg/mL
Sample: Recombinant Human Matrilin-3 (Catalog # 3017-MN)

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Matrilin-3

Matrilin-3 is a 50‑60 kDa extracellular matrix protein that belongs to the superfamily of von Willebrand factor A (VWA) containing proteins. It is primarily expressed in cartilage and functions as a bridging component between proteins of the collagenous matrix (1‑3). The human Matrilin-3 cDNA encodes a 486 amino acid (aa) precursor with a 28 aa signal sequence, an N-terminal VWA domain, four tandem EGF-like repeats, and a C-terminal coiled‑coil domain (4). The Matrilins differ in the number of VWA domains (one or two) and EGF-like repeats (one, three, four, or ten) they contain. Human Matrilin-3 shares 82% aa sequence identity with mouse Matrilin-3. Within the first VWA domain, human Matrilin-3 shares approximately 55% aa sequence identity with human Matrilin-1, -2, and -4. The coiled‑coil domain of Matrilin-3 mediates disulfide-linked homo-oligomerization, with tetramer formation being the most dominant (5‑7). It can also assemble into hetero-oligomers with Matrilin-1 (5‑7). Matrilin-3 is more plentiful than Matrilin-1 in the proliferative zone of the growth plate, whereas the reverse is true in the maturation zone (5). Matrilin-3 interacts directly with Collagen IX and COMP (8, 9). In the absence of Collagen IX, the expression of Matrilin-3 is unchanged, although it is retained inside chondrocytes and is not incorporated into the matrix (9). Matrilin-3 also associates with smaller cartilage fibrils independent of Collagen IX (9). Matrilin-3 knockout mice do not display any obvious abnormalities, suggesting that other molecules may compensate for the lack of Matrilin-3 (10). In contrast, intracellular retention of Matrilin-3 with particular point mutations in the VWA domain results in multiple epiphyseal dysplasia (11‑13). A point mutation in the first EGF-like repeat which has been linked to hand osteoarthritis does not prevent Matrilin-3 secretion (13).

References

  1. Wagener, R. et al. (2005) FEBS Lett. 579:3323.
  2. Deak, F. et al. (1999) Matrix Biol. 18:55.
  3. Whittaker, C.A. and R.O. Hynes (2002) Mol. Biol. Cell 13:3369. 
  4. Belluoccio, D. et al. (1998) Genomics 53:391.
  5. Zhang, Y. and Q. Chen (2000) J. Biol. Chem. 275:32628.
  6. Klatt, A.R. et al. (2000) J. Biol. Chem. 275:3999.
  7. Frank, S. et al. (2002) J. Biol. Chem. 277:19071.
  8. Mann, H.H. et al. (2004) J. Biol. Chem. 279:25294.
  9. Budde, B. et al. (2005) Mol. Cell. Biol. 25:10465.
  10. Ko, Y. et al. (2004) Mol. Cell. Biol. 24:1691.
  11. Jackson, G.C. et al. (2004) J. Med. Genet. 41:52.
  12. Cotterill, S.L. et al. (2005) Hum. Mutat. 26:557.
  13. Otten, C. et al. (2005) J. Med. Genet. 42:774.

Alternate Names

EDM5, HOA, Matrilin3, NDUFC2

Entrez Gene IDs

4148 (Human); 17182 (Mouse)

Gene Symbol

MATN3

Additional Matrilin-3 Products

Product Documents for Human Matrilin-3 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human Matrilin-3 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...